IMC Cannabis Corp. Targets U.S. Market Expansion Amid Regulatory Changes

IMC's Strategic Entry into the U.S. Cannabis Market: A New Horizon for Growth

IM Cannabis Corp. (IMC) announces a pivotal strategy to enter the burgeoning U.S. cannabis market, spurred by recent regulatory changes following President Donald Trump's executive order. This order, issued on December 18, 2025, seeks to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act. This shift acknowledges the medical benefits of cannabis while establishing necessary federal oversight. For IMC, this development opens a significant opportunity to expand its operational footprint beyond its established bases in Israel and Germany, where it has built a reputation for delivering quality medical cannabis products.

To navigate this transition, IMC engages SSC Advisors as financial consultants. Their role is to facilitate the company's entry into the U.S. market and evaluate potential divestitures of its operations in Germany and Israel. This strategic partnership aims to identify suitable partners or acquirers while managing the complexities of the transaction processes. By leveraging SSC Advisors' expertise, IMC positions itself to strategically align its resources and operational capabilities with market opportunities, ensuring a smooth entry into the competitive U.S. landscape.

IMC's commitment to sustainable growth and compliance with regulatory frameworks remains unwavering. The company focuses on delivering premium cannabis products to medical patients, utilizing proprietary data and patient insights to inform its approach. In Germany, through its subsidiary Adjupharm GmbH, IMC distributes cannabis to pharmacies, reinforcing its dedication to quality and patient care. By amplifying its brand presence in high-value markets and fostering a globally sourced supply chain, IMC aims to become a leader in the quality cannabis sector, dedicated to responsible growth and adherence to the strictest regulatory standards.

In addition to its U.S. market aspirations, IMC continues to monitor developments related to the executive order and the federal rescheduling process closely. This vigilance ensures that the company remains agile and responsive to regulatory changes that may impact its operational strategies. As IMC embarks on this new journey, its focus on patient-centered care and compliance will be vital in establishing credibility and trust in the competitive U.S. market.

Overall, IMC's strategic move to enter the U.S. cannabis market represents a significant shift in its operational strategy, aligning with broader industry trends towards regulatory reform and increased acceptance of cannabis for medical use. With a solid foundation in international markets, the company is poised to leverage its experience and insights to navigate the complexities of the U.S. landscape effectively.